Vir Biotechnology Stock News

Wall Street brokerages predict that Vir Biotechnology, Inc. (NASDAQ:VIR) will report sales of $124.06 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Vir Biotechnologys earnings, with the lowest sales estimate coming in at $123.90 million and the highest estimate coming in at $124.21 million. Vir Biotechnology [] The post Vir Biotechnology, Inc. (NASDAQ:VIR) Expected to Announce Quarterly Sales of $124.06 Million appeared first on ETF Daily News .

Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR ) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection. The multi-arm trial, which is being conducted in collaboration with Gilead Sciences, Inc., is assessing various combinations of VIR-2218, Vir''s investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi); selgantolimod (GS-9688), Gilead Sciences'' investigational TLR-8 agonist; and nivolumab, an approved PD-1 inhibitor, in both nucleos(t)ide (NUC)-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive tenofovir alafenamide fumarate (TAF). "For the majority of patients with chronic HBV, a functional cure will likely require a sustained reduction in hepatitis B surface antigen and restoration of the immune response," said Carey Hwang, MD, PhD, senior vice president, clinical research, head of chronic infection for Vir Biotechnology. "We believe the combination of VIR-2218 and two immunomodulatory agents has the potential to improve the HBV-specific immune response and possibly achieve a functional cure.

Vir Biotechnology (NASDAQ:VIR)s stock had its buy rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday, TipRanks reports. They currently have a $199.00 price objective on the stock. HC Wainwrights price objective would indicate a potential upside of 370.00% from the stocks previous close. VIR has []

Vir Biotechnology, Inc. (NASDAQ:VIR) dropped 4.6% on Wednesday . The company traded as low as $40.80 and last traded at $41.00. Approximately 1,423 shares changed hands during trading, a decline of 100% from the average daily volume of 1,224,537 shares. The stock had previously closed at $42.98. VIR has been the subject of a number []

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 11% today. This is why it happened.

The brand name XEVUDY was developed in partnership with Brand Institute, the global leader in pharmaceutical and healthcare-related name development MIAMI, Dec. 7, 2021 /PRNewswire/ -- Brand Insti

GlaxoSmithKline and Vir Biotechnology reported their Covid-19 antibody treatment retained effectiveness against the Omicron variant in laboratory studies.

Yahoo Finance's Anjalee Khemlani details government officials' changes to international travel into the U.S. and the reported effectiveness of GSK-Vir's proposed drug against Omicron variant. Don't Mi

GSK Claims New Anitbody Drug Is Still Effective Against Omicron GSK has just released more data on its new COVID antibody-drug and - surprise, surprise - the company and its American partner claim there is no evidence that the drug is less effective against the omicron variant. GlaxoSmithKline and Vir Biotechnology released the updated preclinical data early Tuesday in the US. The data showed that the pair''s investigational monoclonal antibody sotrovimab continues to show "in vitro activity" against the full known omicron spike protein, according to a statement. This includes 37 identified mutations of the spike protein. Although none of this data has been published in a peer-reviewed medical journal. The data builds on initial preclinical data released last week showing GSK''s antibody drug retains in vitro activity against key individual mutations of the omicron variant. But Tuesday''s data is even more encouraging. "Given the less than three-fold neutralization shift demonstrated in the pre-clinical pseudo- virus assay, which falls below the FDA authorized fact sheet guidance of less than a 5-fold change, we are confident that sotrovimab will continue to provide significant benefit for the early treatment of patients hoping to avoid the most severe consequences of COVID-19," said Vir CEO George Scangos.

GlaxoSmithKline plc confirmed on Tuesday that its COVID-19 therapy jointly developed with Vir Biotechnology is effective against the Omicron coronavirus mutation. "Sotrovimab is the first monocl

--Company to Host Conference Call on Tuesday, December 7, 2021, at 8:30 am ET-- --Company to Host Conference Call on Tuesday, December 7, 2021, at 8:30 am ET--

GlaxoSmithKline plc (NYSE: GSK) said that its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology Inc (NASDAQ: VIR) is effective against all mutations of the new Omicron coronaviru

GSK Singapore is contracted to supply the Government of Singapore with additional doses of sotrovimab, following the first purchase placed by the Ministry of Health (MOH) in June 2021 Sotrovimab was approved by the Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR) for interim authorization in June 2021 SINGAPORE , Dec. 7, 2021 /PRNewswire/ -- GlaxoSmithKline Singapore announced an agreement with the Government of Singapore to supply additional doses of sotrovimab. Sotrovimab is an investigational single-dose monoclonal antibody developed in partnership with Vir Biotechnology, for the treatment of patients with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. This follows the initial purchase agreement signed between GSK Singapore and the government in June 2021 . Priya Kudva Menon , VP and General Manager, GSK Singapore, said: "As we move into the endemic stage of COVID-19 in Singapore , it is clear that multiple treatment options are needed to manage the impact of this virus on people and communities, in addition to vaccinations and other preventative measures.

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Herbert Virgin sold 15,125 shares of the businesss stock in a transaction dated Tuesday, November 30th. The stock was sold at an average price of $49.60, for a total value of $750,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. []

Baillie Gifford & Co. lifted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 1.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,899,692 shares of the companys stock after buying an additional 50,183 shares during the quarter. []